Cryoneurolysis for TKA - a Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Total Knee Arthroplasty (TKA) is also known as a knee replacement. It is one of the most common orthopaedic (bone) surgeries performed and is usually very successful, but some people who have had a knee replacement feel pain that lasts for at least 3 months after surgery and thus continue to take pain control/ analgesic (opioids) medication. Opiates are medications like morphine.

Pain post-surgery can make it difficult to recover and return to daily activities. A better control of pain before the surgery, can help people feel less pain, recover faster, and use less opioids after surgery.

Cryoneurolysis means freezing the nerves that can cause pain. It uses very low temperatures in a specific body part (e.g., nerves to the knee) to freeze the pain nerves and therefore reduce the pain. When applied before the surgery it might help with postoperative pain after knee replacement.

This study will evaluate Iovera, a cryoneurolysis handheld device commercially available in Canada that delivers freezing cold to a target nerve by using nitrous oxide. Cryoneurolysis can relieve pain and symptoms associated with osteoarthritis of the knee for up to 90 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing if Cryoneurolysis Improves Prehabilitation and Decreases Pain After Surgery With Less Opioid Use in TKA Patients

NCT03836313

Arthropathy of Knee Pain, Joint Arthritis Knee +1 more

WITHDRAWN NA

Treatment With Iovera° for Total Knee Arthroplasty (TKA) Post-Operative Pain

NCT03327220

Total Knee Arthroplasty

COMPLETED NA

Intraoperative Posterior Cruciate Ligament (Transcruciate) Injection After Total Knee Arthroplasty (TKA)

NCT01345604

Arthroplasty, Replacement, Knee

COMPLETED PHASE4

Local Infiltration Analgesia During Total Knee Arthroplasty

NCT01305733

Pain

UNKNOWN NA

Opioid Requirements Post Discharge of Patients Having Total Knee Arthroplasty (TKA)

NCT03106129

Knee Arthropathy Opioid Use Pain +1 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients undergoing total knee replacement (TKA) often experience a significant amount of pain during the immediate postoperative period, thus appropriate pain management before, during and after the surgery is a key component of patient satisfaction and better outcomes.

Opioids are the most commonly prescribed drugs to manage postoperative orthopaedic pain; however, their well-known side effects, such as nausea, vomiting and the potential high risk for dependence, can slow down recovery and lead to substance disorders.

Studies have reported, that more than 20% of patients receiving TKA experience persistent and unchanged pain post-surgery. Moreover, 15 to 25% of TKA patients continue the use of opioids at 3 months after surgery, 35% of patients report pain that interferes with their activities of daily living 4 months after surgery.

Adequate pain management before the surgery may prevent or reduce the rate of persistent pain and opioid usage after TKA. Cryoneurolysis is a minimally invasive procedure that uses a small probe to freeze \[at very low temperatures - below -20oC\] the target nerve. It can promote regeneration of the structure and function of the affected nerve. It has shown promising short and long-term results in a variety of acute and chronic pain conditions.

Retrospective studies revealed that preoperative cryoneurolysis might be efficacious in attenuating pain improving function and reducing opioid prescription 12 weeks after TKA. However, the studies are mostly retrospective, with small numbers of patients and not standardized knee specific outcomes.

This is a pilot randomized clinical trial to establish the feasibility of administering the study device (Iovera) to our target population as well as to test and refine the recruitment criteria, study design, patient acceptability, and operational strategies for use in a large definitive study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Pain Chronic Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel-randomized participant-blinded control trial

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Participants and outcomes assessors will be blinded about treatment allocation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Iovera

Cryoneurolysis + standard of care: Usual intervention plus pre-operation Iovera treatment. Patients will receive local anaesthesia unilaterally to the affected knee prior to the treatment and then the anesthesiologist will administer the freezing cold therapy (Iovera device) to the affected knee.

Group Type EXPERIMENTAL

Iovera - Cryoneurolysis

Intervention Type DEVICE

Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.

Placebo

Placebo: Usual intervention plus pre-operation placebo. The placebo group will receive short-acting local anaesthesia injection unilaterally to the affected knee.

Group Type PLACEBO_COMPARATOR

Local anesthetic

Intervention Type DRUG

Placebo - local anaesthesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iovera - Cryoneurolysis

Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.

Intervention Type DEVICE

Local anesthetic

Placebo - local anaesthesia

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients
* 18 to 80 years of age
* Patients with radiographic confirmation and clinical correlation for severe osteoarthritis diagnosis with an indication for total knee replacement
* Patients undergoing primary unilateral total knee replacement
* No previous unilateral knee injection (steroids/biologics) within 6 months of study
* The patient is able to read and understand English and provide informed consent to participation in the study

Exclusion Criteria

* Pregnancy and breastfeeding
* Cryoglobulinemia
* Paroxysmal cold hemoglobinuria
* Cold urticaria
* Raynaud's disease
* Current Opioid use
* History of opiate, narcotic and alcohol abuse
* Revision total knee replacement surgery
* Open and/or infected wounds at or near the affected knee

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No